ELVN
$28.12+0.73 (+2.67%)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor whi...
Recent News
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data
Enliven Therapeutics (ELVN) shares are in focus after the company reported encouraging initial Phase 1b data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients, with efficacy and safety outcomes comparing favorably to existing BCR::ABL1 TKIs. See our latest analysis for Enliven Therapeutics. The latest clinical update appears to have quickly fed into sentiment, with a 1-day share price return of 50.29% at a last close of US$23.25 and year to date share price return of...
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress
Enliven Therapeutics (ELVN) has been quietly grinding through its clinical pipeline, and the stock’s recent move offers a useful snapshot of how investors are weighing early trial risk against long term oncology potential. See our latest analysis for Enliven Therapeutics. The latest pullback to a $20.52 share price comes after a solid 1 month share price return of 16.39%. However, the 1 year total shareholder return of negative 15.97% shows longer term sentiment is still cautious, suggesting...
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect?
The mean of analysts' price targets for Enliven Therapeutics, Inc. (ELVN) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.